Tru-D SmartUVC is an automated, remotely-operated UVC disinfection system that self-adjusts to the size and content dynamics of any room to deliver the proper dose of UVC light energy necessary for complete terminal disinfection. Tru-D is the only UV disinfection device backed by a CDC-funded, randomized clinical trial* to show that it is capable of reducing the transmission of health care-associated infections by 10 – 30 percent. More Tru-Ds have been deployed to disinfect hospitals across the globe than all other competing lookalike offerings, fighting deadly pathogens such as C. diff, MRSA, VRE, MERS, Ebola and many more. An effective and innovative technology backed by sound science, Tru-D is on a mission to eradicate epidemiologically important pathogens (EIPs) making hospitals safer places for patients and staff.
Tru-D leverages ultra-low mercury content Philips Healthcare bulbs, which have a mercury vapor content of only 4.4 mg. In comparison, common fluorescent light bulbs used throughout hospitals have an identical mercury vapor content. The mercury content is well below all CDC/NIOSH/OSHA safety thresholds for use in health care environments. No mercury byproduct is ever emitted from the bulbs. Further, bulb recycling protocols are identical to current hospital process for recycling fluorescent and compact fluorescent bulbs.
Tru-D’s Phillips, low-pressure mercury vapor bulbs provide the most efficient delivery of UVC energy. Unlike any of its competitors, Tru-D safely and effectively destroys all pathogens in its path from a single position in the room without the risk of human error for calculating cycle time or placement. Xenon flash lamps and other unmeasured UV lights, while they may use UVC lamps, have no way of calculating the UV dose needed for each location to determine the positioning or time necessary to disinfect accurately, nor can they reach shadowed or hidden surfaces.
Tru-D’s single placement positioning allows you to work smarter, not harder, implementing seamlessly into any hospital’s workflow. While Tru-D completes a disinfection cycle, EVS workers are free to complete other tasks, rather than having to move the robot to multiple positions. Once the cleaning cycle is complete, Tru-D automatically shuts down and sends an audio and/or text message alert to the operator that disinfection is complete. Tru-D provides a workflow guarantee that ensures integration into labor management and avoids the need for additional FTEs dedicated to Tru-D.
Tru-D’s cycle time varies as it is adjusted to deliver a consistent disinfection outcome from a single position in the room. The room variables affecting cycle time are room size, shape, wall color (reflectivity) and the amount and position of equipment in the room. On the bacteria cycle, validated for 3 to 4 log reduction of MRSA, VRE, CRE and Acinetobacter, the average total cycle time is between 15 to 25 minutes. Bathrooms typically require four to seven minutes.
There is no warmup or cool down period required with Tru-D. The room may be immediately occupied after the completion of the Tru-D cycle.
Tru-D is an acronym for Total Room Ultraviolet Disinfection. Tru-D has a reflective reach of 16’ radius and is capable of disinfecting room surfaces both in line-of–sight and indirect shadowed areas from a single placement in rooms as large as 32’ x 32’ (1000 square feet). Tru-D’s measured dose capability alters cycle times based upon room variables (size, shape, color or reflective properties and the amount of equipment in the room). Ceiling height does not affect Tru-D’s disinfection capabilities on touchable surfaces.
Tru-D has an integral patent protected sensor array called Sensor360. The sensor array measures reflected UVC dose from walls, doors and ceilings. Numerous third-party scientific validations ensure the Tru-D method of measured UVC light energy delivers a lethal disinfecting dose into all direct (line-of-sight) and indirect (shadowed) areas.
Tru-D has two settings: bacteria and spore. Third-party, Tru-D-specific validations are related to MRSA, VRE and Acinetobactor though all bacterial pathogens are disinfected on the bacteria dose setting. Third-party Tru-D-specific validations for spores are related to C-diff and Anthrax though all spores are disinfected on the spore setting. Average cycle times in single patient rooms are 15 to 25 minutes for bacteria and 20 to 35 minutes on spores.
Tru-D’s Sensor360 technology identifies the proper UVC dosage needed to destroy all dangerous organisms within the visible and shadowed spaces in a targeted room. After a full cycle, Tru-D’s intuitive tablet controller pings the user to message the cycle is complete and Tru-D is ready for the next targeted room. Tru-D’s dosage algorithms allow us to claim guaranteed terminal room disinfection. Tru-D has been proven by more than a dozen third-party studies to deliver up to 99.9 percent pathogen reduction effective in ridding health care environments of EIPs inclusive of bacteria, viruses, spores and fungi.
Data concludes that a patient admitted to a room previously occupied by an infected patient has an increased risk of 39 – 353% of acquiring the infection of the previous patient. The results of the recent Benefits of Enhanced Terminal Room Disinfection (BETR-D) study funded by the CDC validated that enhanced terminal room disinfection strategies, inclusive of Tru-D, reduced the risk of acquisition and infection caused by target multidrug-resistant organisms by 10 – 30 percent. The overall goal of the study was to determine if different room cleaning strategies can help prevent acquisition of superbugs such as MRSA, C. diff, VRE and Acinetobacter, and it achieved its objective.
Tru-D’s intuitive tablet controller, iTru-D, delivers disinfection data automatically to a secure, cloud-based portal – myTru-D – that hospital staff and administrators can access through any web browser. Data provided by iTru-D is viewable through concise graphics and exportable spreadsheets and reports when and where Tru-D is being used, for how long and by whom, optimizing Tru-D’s ability to improve health care outcomes.
After twelve device-specific validations that have been published in third-party literature conclusive of Tru-D’s capability to thoroughly disinfect the room, the Centers for Disease Control, Duke University and UNC research teams selected Tru-D for a large scale, well-controlled randomized clinical trial. While Tru-D maintains a library of anecdotal reports of infection reduction with 300 Tru-D devices in use daily, we find it irresponsible to use these reports without discerning committees undergoing structured due diligence processes. Competitor references to small-scale, HAI outcome reduction studies either contain a strong conflict of interest due to company authorship and influence and statements of financial support. Additionally, a close reading of the literature discloses that the limited data does not allow separation of confounding protocols including hand-washing, manual disinfection techniques and other infection prevention protocols. Only Tru-D can make an HAI reduction claim based upon the gold standard of evidence based practice, a large-scale randomized clinical trial.
Tru-D was the only device of its kind selected for the study due to its patented Sensor360 technology that analyzes a space to administer a proper UV dose while eliminating human error in cleaning strategies. Dan Sexton MD, Research Lead for the BETR-D study, stated only Tru-D was selected “…because its automated system is proven to significantly reduce environmental pathogens and eliminate human error in the disinfection process.”
- Tru-D delivers a precisely-measured UVC dose that ensures a validated baseline of disinfection and consistent quality of care
- Tru-D guarantees total room disinfection, including shadowed surfaces, from a single placement
- Tru-D disinfection claims are supported by multiple device-specific, third-party validations with no conflict of interest disclosures, including the only CDC-funded randomized clinical trial on UV disinfection
- Tru-D’s single placement and measured dose eliminate human error associated with competing multiple placement devices with fixed cycle times
- Tru-D maximizes operator efficiency, provides uncomplicated throughput and is implemented seamlessly within a hospital’s current workforce without additional FTE’s
- Tru-D provides meaningful disinfection data through a secure portal that is cloud-based as well as clear and precise report mechanisms with real-time disinfection data
*The CDC-Funded Epicenter Benefits of Enhanced Terminal Room Disinfection (BETR-D) Study was a device- and method-specific multi-phase, randomized clinical trial conducted across nine hospitals of varying size and census. The research team combined expert resources from Duke University Health System and University of North Carolina School of Medicine. Tru-D was the only device selected for the CDC-funded study due to its unique proven capability to reduce environmental pathogens by measuring the necessary reflective dose required to thoroughly disinfect hospital rooms and deliver a baseline of disinfection critical to a randomized clinical trial.